<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pmed</journal-id><journal-id journal-id-type="flc">plme</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>PLoS Medicine</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0040043</article-id><article-id pub-id-type="publisher-id">06-PLME-C-0990</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correspondence</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Biochemistry</subject>
          <subject>Cardiovascular Disorders</subject>
          <subject>Cell Biology</subject>
          <subject>Diabetes and Endocrinology</subject>
          <subject>Infectious Diseases</subject>
          <subject>Virology</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>Cardiovascular Medicine</subject>
          <subject>HIV Infection/AIDS</subject>
          <subject>Ischemic heart disease</subject>
          <subject>Nutrition and Metabolism</subject>
        </subj-group>
      </article-categories><title-group><article-title>HIV and Cardiovascular Disease: Contribution of HIV-Infected Macrophages to Development of Atherosclerosis</article-title><alt-title alt-title-type="running-head">Correspondence</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Bukrinsky</surname>
            <given-names>Michael</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Sviridov</surname>
            <given-names>Dmitri</given-names>
          </name>
        </contrib>
      </contrib-group><author-notes>
        <fn fn-type="current-aff" id="n3">
          <p>Michael Bukrinsky (<email xlink:type="simple">mtmmib@gwumc.edu</email>)</p>
        </fn>
        <fn fn-type="current-aff" id="n4">
          <p>George Washington University, Washington, District of Columbia, United States of America</p>
        </fn>
        <fn fn-type="current-aff" id="n5">
          <p>Dmitri Sviridov, Baker Heart Research, Institute Melbourne, Victoria, Australia</p>
        </fn>
      <fn fn-type="conflict" id="n2">
        <p> The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>1</month>
        <year>2007</year>
      </pub-date><pub-date pub-type="epub">
        <day>30</day>
        <month>1</month>
        <year>2007</year>
      </pub-date><volume>4</volume><issue>1</issue><elocation-id>e43</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2007</copyright-year><copyright-holder>Bukrinsky and Sviridov</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article page="e496" related-article-type="companion" vol="3" xlink:href="info:doi/10.1371/journal.pmed.0030496" xlink:title="Perspectives" xlink:type="simple">
				<article-title>Does HIV Cause Cardiovascular Disease?</article-title>
			</related-article><funding-group><funding-statement>The authors received no specific funding for this article.</funding-statement></funding-group><counts>
        <page-count count="1"/>
      </counts><!--===== Restructure custom-meta-wrap to custom-meta-group =====--><custom-meta-group>
        <custom-meta>
          <meta-name>citation</meta-name>
          <meta-value>Bukrinsky M, Sviridov D (2007) HIV and cardiovascular disease: Contribution of HIV-infected macrophages to development of atherosclerosis. PLoS Med 4(1): e43. doi: <ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0040043" xlink:type="simple">10.1371/journal.pmed.0040043</ext-link></meta-value>
        </custom-meta>
      </custom-meta-group></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title/>
      <p>In their Perspective published in <italic>PLoS Medicine</italic> [<xref ref-type="bibr" rid="pmed-0040043-b001">1</xref>], Carr and Ory provide a fair review of our recent paper in <italic>PLoS Biology</italic> [<xref ref-type="bibr" rid="pmed-0040043-b002">2</xref>]. However, we believe their commentary puts too much emphasis on the role of low high-density lipoprotein (HDL) cholesterol levels as a cause of atherosclerosis in HIV-infected patients. While HDL cholesterol levels are reduced in untreated HIV infection [<xref ref-type="bibr" rid="pmed-0040043-b003">3</xref>], and defects in reverse cholesterol transport (RCT) that we reported may well be a contributing factor to this abnormality, initiation of antiretroviral therapy restores HDL levels [<xref ref-type="bibr" rid="pmed-0040043-b004">4</xref>]. Although the development of dyslipidemia with prolonged use of anti-HIV drugs again lowers HDL cholesterol and in addition raises very low-density lipoprotein and low-density lipoprotein levels [<xref ref-type="bibr" rid="pmed-0040043-b005">5</xref>], it is unlikely that HIV infection contributes significantly to these effects. Indeed, most HDL comes from the liver and intestine, which are responsible for maintaining plasma HDL levels [<xref ref-type="bibr" rid="pmed-0040043-b006">6</xref>], but neither hepatocytes nor enterocytes are infected by HIV. Also, the number of HIV-infected cells in treated patients is relatively low to account for any general changes in concentration of plasma lipoproteins.</p>
      <p>We suggest a different model that provides a simple connection between HIV-induced impairment of the cellular step of RCT and pathogenesis of atherosclerosis. We propose that RCT-defective HIV-infected macrophages contribute to development of atherosclerosis in HIV patients by converting into foam cells and initiating plaque formation in the vessel wall. Indeed, specific inactivation of <italic>ABCA1</italic> in macrophages has been shown to induce atherosclerosis in a mouse model independently from plasma HDL level [<xref ref-type="bibr" rid="pmed-0040043-b007">7</xref>]. Plaque formation through this mechanism can begin even on the background of normal HDL but would be greatly accelerated by dyslipidemia, a condition observed in HIV patients treated with antiretroviral therapy. Given that even fully suppressive HAART (highly active antiretroviral therapy) does not eliminate long-lived productive reservoirs of the virus and that macrophages are a likely potential component of these reservoirs [<xref ref-type="bibr" rid="pmed-0040043-b008">8</xref>], long-lived HIV-infected macrophages may contribute to atherosclerotic plaque formation long after initiation of HAART. Consistent with this hypothesis, it was found that the majority of cardiovascular events in HIV-infected patients are “one plaque” events [<xref ref-type="bibr" rid="pmed-0040043-b009">9</xref>].</p>
      <p>Therefore, several lines of evidence indirectly implicate HIV-infected macrophages in the pathogenesis of atherosclerosis in HIV patients. Future studies will determine the role of HIV-induced RCT impairment in this process and are expected to provide an understanding of the connection between HIV infection and atherosclerosis and to identify novel treatment targets for both diseases.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pmed-0040043-b001">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Carr</surname><given-names>A</given-names></name><name name-style="western"><surname>Ory</surname><given-names>D</given-names></name></person-group>
					<year>2006</year>
					<article-title>Does HIV cause cardiovascular disease?</article-title>
					<source>PLoS Med</source>
					<volume>3</volume>
					<fpage>e496</fpage>
					<comment>doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030496" xlink:type="simple">10.1371/journal.pmed.0030496</ext-link></comment>
				</element-citation>
      </ref>
      <ref id="pmed-0040043-b002">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Mujawar</surname><given-names>Z</given-names></name><name name-style="western"><surname>Rose</surname><given-names>H</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>MP</given-names></name><name name-style="western"><surname>Pushkarsky</surname><given-names>T</given-names></name><name name-style="western"><surname>Dubrovsky</surname><given-names>L</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Human immunodeficiency virus impairs reverse cholesterol transport from macrophages.</article-title>
					<source>PLoS Biol</source>
					<volume>4</volume>
					<fpage>e365</fpage>
					<comment>doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pbio.0040365" xlink:type="simple">10.1371/journal.pbio.0040365</ext-link></comment>
				</element-citation>
      </ref>
      <ref id="pmed-0040043-b003">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Grunfeld</surname><given-names>C</given-names></name><name name-style="western"><surname>Pang</surname><given-names>M</given-names></name><name name-style="western"><surname>Doerrler</surname><given-names>W</given-names></name><name name-style="western"><surname>Shigenaga</surname><given-names>JK</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>P</given-names></name><etal/></person-group>
					<year>1992</year>
					<article-title>Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.</article-title>
					<source>J Clin Endocrinol Metab</source>
					<volume>74</volume>
					<fpage>1045</fpage>
					<lpage>1052</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040043-b004">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>van der Valk</surname><given-names>M</given-names></name><name name-style="western"><surname>Kastelein</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>RL</given-names></name><name name-style="western"><surname>van Leth</surname><given-names>F</given-names></name><name name-style="western"><surname>Katlama</surname><given-names>C</given-names></name><etal/></person-group>
					<year>2001</year>
					<article-title>Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.</article-title>
					<source>AIDS</source>
					<volume>15</volume>
					<fpage>2407</fpage>
					<lpage>2414</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040043-b005">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Crook</surname><given-names>MA</given-names></name><name name-style="western"><surname>Mir</surname><given-names>N</given-names></name></person-group>
					<year>1999</year>
					<article-title>Abnormal lipids and the acquired immunodeficiency syndrome: Is there a problem and what should we do about it?</article-title>
					<source>Int J STD AIDS</source>
					<volume>10</volume>
					<fpage>353</fpage>
					<lpage>356</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040043-b006">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Singaraja</surname><given-names>RR</given-names></name><name name-style="western"><surname>van Eck</surname><given-names>M</given-names></name><name name-style="western"><surname>Bissada</surname><given-names>N</given-names></name><name name-style="western"><surname>Zimetti</surname><given-names>F</given-names></name><name name-style="western"><surname>Collins</surname><given-names>HL</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo.</article-title>
					<source>Circulation</source>
					<volume>114</volume>
					<fpage>1301</fpage>
					<lpage>1309</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040043-b007">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Aiello</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Brees</surname><given-names>D</given-names></name><name name-style="western"><surname>Bourassa</surname><given-names>PA</given-names></name><name name-style="western"><surname>Royer</surname><given-names>L</given-names></name><name name-style="western"><surname>Lindsey</surname><given-names>S</given-names></name><etal/></person-group>
					<year>2002</year>
					<article-title>Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages.</article-title>
					<source>Arterioscler Thromb Vasc Biol</source>
					<volume>22</volume>
					<fpage>630</fpage>
					<lpage>637</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040043-b008">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Pomerantz</surname><given-names>RJ</given-names></name></person-group>
					<year>2003</year>
					<article-title>Reservoirs, sanctuaries, and residual disease: The hiding spots of HIV-1.</article-title>
					<source>HIV Clin Trials</source>
					<volume>4</volume>
					<fpage>137</fpage>
					<lpage>143</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040043-b009">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Stewart</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>D</given-names></name><name name-style="western"><surname>Becker</surname><given-names>A</given-names></name><name name-style="western"><surname>Askew</surname><given-names>D</given-names></name><name name-style="western"><surname>Ntyintyane</surname><given-names>L</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Mapping the emergence of heart disease in a black, urban population in Africa: The Heart of Soweto Study.</article-title>
					<source>Int J Cardiol</source>
					<volume>108</volume>
					<fpage>101</fpage>
					<lpage>108</lpage>
				</element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>